ReviewRheumatology and therapy2016
Review of Osteosarcoma and Current Management.
Review in Rheumatology and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
225 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.Cancer medicine · 2024Pooled it
- Identification of key genes in osteosarcoma by meta‑analysis of gene expression microarray.Molecular medicine reports · 2019Pooled it
- Extraosseous osteochondroma of the hypothenar region: a case report and literature review.BMC musculoskeletal disorders · 2026Review
- Outcomes of Megaprosthetic Reconstruction After Tumor Resection of the Distal Femur and Proximal Tibia: A Single-Center Retrospective Study of 241 Cases.Journal of clinical medicine · 2026Article
- Does mifamurtide affect the elimination of high-dose methotrexate in children with osteosarcoma?Cancer chemotherapy and pharmacology · 2026Article
- Construction and validation of a novel prognostic signature that correlates with immune infiltration based on glycolysis related lncRNAs in osteosarcoma.Discover oncology · 2026Article
- ADAR2 induces the differentiation of osteosarcoma cells by editing activity on IGFBP7: new implications for therapy.Bone research · 2026Article
- A 3D Bioprinted Spheroid-Laden dECM-Enriched Osteosarcoma Model for Enhanced Drug Testing and Therapeutic Discovery.Advanced healthcare materials · 2026Article
- Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway.Journal for immunotherapy of cancer · 2026Article
- Histotripsy treatment reduces tumor burden and extends survival in an orthotopic mouse model of osteosarcoma.Frontiers in oncology · 2026Article
- Comparative clinical and prognostic significance of integrin αvβ3, αvβ5, and αvβ6 in osteosarcoma.Frontiers in oncology · 2026Article
- Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma.Frontiers in medicine · 2026Article
- Efficacy of Stereotactic Body Radiotherapy in Osteosarcoma Bone Metastases.Journal of pediatric hematology/oncology · 2026Article
- Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer.Oncology research · 2026Review
- Periosteal Osteosarcoma: Emerging Clinical Concepts, Evolving Treatment Options: A Narrative Review.Current pain and headache reports · 2025Review
- Reinvestigating Pyrrol-2-One-Based Compounds: From Antimicrobial Agents to Promising Antitumor Candidates.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Inflammation-driven prognostic model and immune landscape profiling in osteosarcoma.Discover oncology · 2025Article
- Factors Associated with Bone Union Failure After Frozen Autograft Reconstruction in Lower Limb Osteosarcoma.Cancers · 2025Article
- Functional personalized complex combination nano therapy for osteosarcoma.Scientific reports · 2025Article
- Recent Advances in the Development of Metal-Glycoconjugates for Medicinal Applications.Molecules (Basel, Switzerland) · 2025Review
165 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical management of this tumor. Finally, the review will discuss some of the novel approaches to treating this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.